Valuation — not yet established
No valuation for SmithRx is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($5.5M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for SmithRx
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jul 2018 | Early Stage VC (Series A2) | $5.5M | ▮ | ▮ |
How SmithRx's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For SmithRx, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has SmithRx raised?
- SmithRx has raised $5.5M in total funding across 1 recorded rounds.
- When did SmithRx last raise?
- SmithRx last raised in Jul 2018 (Early Stage VC (Series A2)), raising $5.5M.